Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi-Sheng Chang, Wan-Ju Lee, Chen-Chee Lim, Shih-Hao Wang, Sheng-Min Hsu, Yi-Chian Chen, Chia-Yi Cheng, Yu-Ti Teng, Yi-Hsun Huang, Chun-Chieh Lai, Sung-Huei Tseng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bf60fbae34e04c8eb45e500e819ecf7d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bf60fbae34e04c8eb45e500e819ecf7d
record_format	dspace
spelling	oai:doaj.org-article:bf60fbae34e04c8eb45e500e819ecf7d2021-12-02T11:40:55ZReal-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan10.1038/s41598-018-25864-02045-2322https://doaj.org/article/bf60fbae34e04c8eb45e500e819ecf7d2018-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-25864-0https://doaj.org/toc/2045-2322Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.Yi-Sheng ChangWan-Ju LeeChen-Chee LimShih-Hao WangSheng-Min HsuYi-Chian ChenChia-Yi ChengYu-Ti TengYi-Hsun HuangChun-Chieh LaiSung-Huei TsengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
description	Abstract This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients with nAMD, who applied for ranibizumab covered by national health insurance. A total of 194 eyes (73.5%) in 179 patients (65.5% men; mean ± standard deviation age 69.4 ± 10.7 years) were pre-approved for treatment. Applications for treatment increased year by year, but approval rates decreased during this time. The major causes of rejection for funding were diseases mimicking nAMD, including macular pucker/epiretinal membrane, macular scarring, dry-type AMD, and possible polypoidal choroidal vasculopathy. After completion of three injections in 147 eyes, visual acuity significantly improved, gaining ≥1 line in 51.8% of eyes and stabilising in 38.3% of 141 eyes in which visual acuity was measured. The 114 eyes approved with only one application had a better visual outcome than the 27 eyes approved after the second or third applications. In conclusion, ranibizumab is effective for nAMD; however, approval after the second or third application for national health insurance cover is a less favourable predictor of visual outcome.
format	article
author	Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng
author_facet	Yi-Sheng Chang Wan-Ju Lee Chen-Chee Lim Shih-Hao Wang Sheng-Min Hsu Yi-Chian Chen Chia-Yi Cheng Yu-Ti Teng Yi-Hsun Huang Chun-Chieh Lai Sung-Huei Tseng
author_sort	Yi-Sheng Chang
title	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_short	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_full	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_fullStr	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_full_unstemmed	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
title_sort	real-world use of ranibizumab for neovascular age-related macular degeneration in taiwan
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/bf60fbae34e04c8eb45e500e819ecf7d
work_keys_str_mv	AT yishengchang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT wanjulee realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chencheelim realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT shihhaowang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT shengminhsu realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yichianchen realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chiayicheng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yutiteng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT yihsunhuang realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT chunchiehlai realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan AT sunghueitseng realworlduseofranibizumabforneovascularagerelatedmaculardegenerationintaiwan
_version_	1718395543337566208

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Ejemplares similares